Previous close | 0.0200 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 2.1300 |
Strike | 175.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0100 - 0.0200 |
Contract range | N/A |
Volume | |
Open interest | 114 |
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide). The study, presented at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients with this genetic profile would be strong responders to the treatment. Related: Changing Frugal Eating Habits-How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending. Th
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.